Brief: Cynata Therapeutics Says Cyp-001S FDA Approval Pathway Not Impeded
16/05/2025 07:08
May 16 (Reuters) - Cynata Therapeutics Ltd CYP.AX: CYP-001S FDA APPROVAL PATHWAY NOT IMPEDED CONSIDERS ORPHAN-DRUG EXCLUSIVITY RECENTLY GRANTED BY US FDA WILL NOT IMPEDE APPROVAL OF CYP-001 Further company coverage: CYP.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cynata Therapeutics
See all newsBrief: Cynata Therapeutics Says Firm Commitments Received To Raise Further A$550,000 Via Placement
Brief: Cynata Therapeutics Enters Consultancy Agreement With LIR Bio Advisory
Brief: Cynata Therapeutics Establishes Share Sale Facility For Unmarketable Parcel Holders
Brief: Cynata Therapeutics Terminates Of At-The-Market Subscription Deed
Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million